null

SMILES: CN(C)c1ccc2c(-c3ccc(s3)C(=S)N3CCCCC3)c3ccc(cc3[se]c2c1)=[N+](C)C

InChI Key: InChIKey=RQPFVWVAMDKMPO-UHFFFAOYSA-N

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 50249852   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
ATP-dependent translocase ABCB1 (Homo sapiens (Human))	BDBM50249852 (3,6-Bis(dimethylamino)-9-(N-piperidyl-2-thienyl-5-...) Show SMILES CN(C)c1ccc2c(-c3ccc(s3)C(=S)N3CCCCC3)c3ccc(cc3[se]c2c1)=[N+](C)C |(6.12,-24.59,;7.46,-25.36,;7.46,-26.9,;8.79,-24.59,;8.79,-23.05,;10.12,-22.27,;11.46,-23.04,;12.79,-22.25,;12.79,-20.71,;11.54,-19.81,;12,-18.35,;13.54,-18.34,;14.03,-19.8,;14.44,-17.09,;13.8,-15.68,;15.96,-17.24,;16.59,-18.63,;18.1,-18.79,;19,-17.55,;18.37,-16.15,;16.85,-15.99,;14.15,-23.03,;15.49,-22.24,;16.84,-23.01,;16.85,-24.58,;15.5,-25.36,;14.15,-24.59,;12.81,-25.36,;11.46,-24.59,;10.13,-25.36,;18.19,-25.34,;18.2,-26.88,;19.52,-24.56,)| Show InChI InChI=1S/C27H30N3S2Se/c1-28(2)18-8-10-20-24(16-18)33-25-17-19(29(3)4)9-11-21(25)26(20)22-12-13-23(32-22)27(31)30-14-6-5-7-15-30/h8-13,16-17H,5-7,14-15H2,1-4H3/q+1	PDB UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	9.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
The State University of New York Curated by ChEMBL					Assay Description Inhibition of verapamil-stimulated ATPase activity of human histidine10-tagged MDR1 expressed in BHK cells				J Med Chem 52: 3328-41 (2009) Article DOI: 10.1021/jm900253g BindingDB Entry DOI: 10.7270/Q29Z94SF
					More data for this Ligand-Target Pair
ATP-dependent translocase ABCB1 (Homo sapiens (Human))	BDBM50249852 (3,6-Bis(dimethylamino)-9-(N-piperidyl-2-thienyl-5-...) Show SMILES CN(C)c1ccc2c(-c3ccc(s3)C(=S)N3CCCCC3)c3ccc(cc3[se]c2c1)=[N+](C)C |(6.12,-24.59,;7.46,-25.36,;7.46,-26.9,;8.79,-24.59,;8.79,-23.05,;10.12,-22.27,;11.46,-23.04,;12.79,-22.25,;12.79,-20.71,;11.54,-19.81,;12,-18.35,;13.54,-18.34,;14.03,-19.8,;14.44,-17.09,;13.8,-15.68,;15.96,-17.24,;16.59,-18.63,;18.1,-18.79,;19,-17.55,;18.37,-16.15,;16.85,-15.99,;14.15,-23.03,;15.49,-22.24,;16.84,-23.01,;16.85,-24.58,;15.5,-25.36,;14.15,-24.59,;12.81,-25.36,;11.46,-24.59,;10.13,-25.36,;18.19,-25.34,;18.2,-26.88,;19.52,-24.56,)| Show InChI InChI=1S/C27H30N3S2Se/c1-28(2)18-8-10-20-24(16-18)33-25-17-19(29(3)4)9-11-21(25)26(20)22-12-13-23(32-22)27(31)30-14-6-5-7-15-30/h8-13,16-17H,5-7,14-15H2,1-4H3/q+1	PDB UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	9.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
The State University of New York Curated by ChEMBL					Assay Description Inhibition of human MDR1 expressed in MDCK2 cells assessed as enhancement of Calcein-AM uptake treated 30 mins before Calcein-AM challenge measured a...				J Med Chem 52: 3328-41 (2009) Article DOI: 10.1021/jm900253g BindingDB Entry DOI: 10.7270/Q29Z94SF
					More data for this Ligand-Target Pair